## Lung Cancer: Small Cell Lung Cancer Pathways

<table>
<thead>
<tr>
<th>Patient Name:</th>
<th>Date of Birth:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Member Number:</td>
<td>Treatment Start Date:</td>
</tr>
</tbody>
</table>

### Pathology:

- **Line of Therapy:**
  - Neoadjuvant/Pre-Op
  - Adjuvant/Post-Op
  - 1st Line
  - 2nd Line
  - 3rd Line
  - 3rd Line+
  - Maintenance

### Biomarkers/Characteristics:

- **ALK Status:**
  - Negative
  - Positive
  - Not Reported

- **EGFR:**
  - Negative
  - Positive
  - Not Reported

- **BRAF:**
  - V600E Mutation
  - V600K Mutation
  - Wild Type
  - Not Reported

- **MET Amplification:**
  - Negative
  - Positive
  - Not Reported

- **RET Gene Rearrangement:**
  - Absent
  - Present
  - Not Reported

- **ROS1 Rearrangement:**
  - Negative
  - Positive
  - Not Reported

- **BRAF V600E Mutation:**
  - V600K Mutation
  - Wild Type
  - Not Reported

### Limited Stage | Primary, Adjuvant, or First Line of Therapy (1st Line)

- Carboplatin and etoposide (Toposar) ± XRT
- Cisplatin and etoposide (Toposar) ± XRT

### Extensive Stage | First Line of Therapy (1st Line)

- Carboplatin and etoposide (Toposar)
- Atezolizumab (Tecentriq), carboplatin, and etoposide

### Second and Subsequent Lines of Therapy (2nd Line+) | Relapse Greater than Six (6) Months

- Carboplatin and etoposide (Toposar)

---

**Note:** Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered “on pathway.” However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.